Lilly stock caught up in wave of uncertainty
After a stunning 703% run-up in price over the past five years, shares of Eli Lilly and Co. have been on a roller-coaster ride since September.
Share prices
-
Lilly stock skyrockets, raising profile of city’s life sciences sector
The pharmaceutical company has launched 20 drugs in the past decade to treat diseases from arthritis and psoriasis to diabetes and cancer. In recent months, Lilly has overtaken every competitor to become the most valuable drugmaker in the world.
Read More -
Investors wary as Elanco pins hopes on new products
Shares in the animal health care company have lost more than two-thirds of their value in the past 18 months, but Elanco says a bevy of new products in its pipeline will prove an era of strong growth is yet to come.
Read More -
SPACs sound arcane, but make buckets of money for Indy investors
A nontraditional way to take companies public is booming on Wall Street, leading to an unprecedented explosion of deals.
Read More
Articles
Rebounding banks see tailwinds ahead
After a tough 2023, most publicly traded banks in the Hoosier state have seen at least a partial rebound in their stock prices this year.
Lilly inches toward rare $1 trillion market-value distinction
The spotlight is turning to Indianapolis-based Eli Lilly and Co. as the next possible member of the so-called “Trillion-Dollar Club,” based on the drugmaker’s climbing stock price and swelling demand for its treatments for diabetes, obesity and other diseases.
Lilly employees have seen big wins as stock price surges 500% since 2019
In the past 52 weeks, shares have set new records almost every week, due to investor eagerness over the company’s new drugs for obesity and diabetes, two health conditions that plague America, along with other drugs in the pipeline.
As Lilly stock skyrockets, endowment gifts surge
In recent weeks, the Indianapolis-based philanthropy has been unveiling a flurry of gifts at the $100 million level or higher.
Indiana-based banks see stock-price rebound on horizon
Most of Indiana’s 14 publicly traded banks have seen a significant drop in stock prices at some point this year, in some cases falling more than 50% from their Jan. 3 prices, the first trading day of the year.
Inotiv facing shareholder lawsuit over stock drop
The West Lafayette-based pharmaceutical testing company has seen its stock price soar—and later plunge—following its announcement last fall that it planned to acquire Indianapolis-based Envigo RMS LLC, which breeds and sells animals used in lab testing.
Indiana stocks fare better than most this year
At the close of trading June 24, Bloomberg’s Indiana Index was trading at $375.30, up 0.55% from the beginning of the year. The S&P 500 was down 18.45% and the tech-heavy Nasdaq was down 26.59%.
Elanco shares plunge 15% after mixed full-year outlook
Shares of the Greenfield-based maker of animal feeds and vaccines dove after the firm warned that it’s facing inflationary pressures, increased logistics costs and other headwinds.
Real estate firm’s bet on senior health care takes painful turn
The past year has been awful for Carmel-based Invesque, as COVID-19 hurt the full gamut of its health care real estate portfolio, from nursing homes and office buildings to memory-care and assisted-living centers.
Lilly’s flush pipeline makes it Wall Street darling
If you follow the daily drumbeat of news emanating out of Lilly Corporate Center, you might not grasp how phenomenally well the company is poised to perform in the coming years.
After Biglari unleashes venom on Cracker Barrel, CEO fires back
Biglari Holdings’ Sardar Biglari is pushing for reforms at Cracker Barrel Old Country Store even as Biglari restaurant Steak n Shake teeters.
Executives without answers try to salve jittery investors
Many of Indiana’s 54 public companies have withdrawn their earnings guidance for the year, even as executives emphasize their belief that they are positioned well for the long term.
Investors unforgiving after ANGI Homeservices stumbles
Investors in Angie’s List Inc. appeared to have hit the jackpot two years ago after the company merged with rival HomeAdvisor. Unfortunately, that love affair is officially over.
What’s next for Simon Property Group’s sagging stock price?
The company’s shares—like those of many in retail real estate—are out of favor, as investors wring their hands over retail bankruptcies and the long-term impact of e-commerce.
Indiana stocks rocket higher to open year
More than two dozen of the state’s 51 public companies posting double-digit percentage gains in the first quarter.
Lilly shares dip due to drug failure, lowered forecast
The Indianapolis-based pharmaceutical giant on Wednesday tempered expectations for its earnings in 2019 after a promising cancer drug failed to pan out and the firm prepared for big acquisition.
Novartis nearly doubled its Endocyte bid during drawn-out courtship
The escalation in per-share price—which far exceeds that of other recent deals involving Indiana public companies—reflects the unique nature of M&A in the pharmaceutical realm.
Calumet Specialty’s new CEO giving it second lease on life
Calumet shares now trade around $6.65, nearly double their October 2016 low but way down from October 2015, when they fetched around $27.
Finish Line’s merger with British suitor could pose challenge to Foot Locker
Combining Indianapolis-based Finish Line Inc. and JD Sports Fashion from across the pond could create a firm within striding distance of the sports apparel industry’s heavyweight, according to an analyst.